- Home
- MDCX vs ACRV Comparison
MDCX vs ACRV Comparison
Compare MDCX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- ACRV
- Stock Information
- Founded
- MDCX 2008
- ACRV 2018
- Country
- MDCX United States
- ACRV United States
- Employees
- MDCX N/A
- ACRV N/A
- Industry
- MDCX
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- MDCX
- ACRV Health Care
- Exchange
- MDCX Nasdaq
- ACRV Nasdaq
- Market Cap
- MDCX 50.8M
- ACRV 47.8M
- IPO Year
- MDCX N/A
- ACRV 2022
- Fundamental
- Price
- MDCX $2.21
- ACRV $2.41
- Analyst Decision
- MDCX Strong Buy
- ACRV Buy
- Analyst Count
- MDCX 2
- ACRV 5
- Target Price
- MDCX $23.50
- ACRV $14.67
- AVG Volume (30 Days)
- MDCX 294.5K
- ACRV 1.2M
- Earning Date
- MDCX 11-14-2025
- ACRV 11-13-2025
- Dividend Yield
- MDCX N/A
- ACRV N/A
- EPS Growth
- MDCX N/A
- ACRV N/A
- EPS
- MDCX N/A
- ACRV N/A
- Revenue
- MDCX N/A
- ACRV N/A
- Revenue This Year
- MDCX N/A
- ACRV N/A
- Revenue Next Year
- MDCX N/A
- ACRV $805.34
- P/E Ratio
- MDCX N/A
- ACRV N/A
- Revenue Growth
- MDCX N/A
- ACRV N/A
- 52 Week Low
- MDCX $1.79
- ACRV $1.05
- 52 Week High
- MDCX $8.94
- ACRV $8.00
- Technical
- Relative Strength Index (RSI)
- MDCX 44.73
- ACRV 62.55
- Support Level
- MDCX $2.16
- ACRV $2.00
- Resistance Level
- MDCX $2.55
- ACRV $2.35
- Average True Range (ATR)
- MDCX 0.18
- ACRV 0.20
- MACD
- MDCX -0.01
- ACRV 0.03
- Stochastic Oscillator
- MDCX 13.34
- ACRV 89.28
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.